Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Onyx Pharmaceuticals fell 78 cents (-1%) to $75.33 on average volume. Throughout the day, 865,565 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 961,900 shares. The stock ranged in price between $74.49-$77.21 after having opened the day at $76.98 as compared to the previous trading day's close of $76.11. Other companies within the Drugs industry that declined today were: Oxygen Biotherapeutics ( OXBT), down 11.5%, Opexa Therapeutics ( OPXA), down 10.5%, OxiGene ( OXGN), down 8.1%, and Medgenics ( MDGN), down 8.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $5.21 billion and is part of the health care sector. The company has a P/E ratio of 66.9, above the S&P 500 P/E ratio of 17.7. Shares are up 2.8% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

On the positive front, Prima Biomed ( PBMD), up 22%, Oncolytics Biotech ( ONCY), up 21.9%, Galectin Therapeutics ( GALT), up 12%, and Celsion Corporation ( CLSN), up 11.2%, were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan